Publications

Export 115 results:
Auteur Title Type [ Année(Desc)]
Filtres: Auteur is Pedro Rosa-Neto  [Enlever les filtres]
2018
Meyer P-F, Savard M, Poirier J, Labonte A, Rosa-Neto P, Weitz TM, Town T, Breitner JCS.  2018.  Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer's Disease Pathogenesis.. J Alzheimers Dis. 63(2):577-590.
Li X, Ba M, Ng KPin, Mathotaarachchi S, Pascoal TA, Rosa-Neto P, Gauthier S.  2018.  Characterizing biomarker features of cognitively normal individuals with ventriculomegaly.. Alzheimers Dement (Amst). 10:12-21.
Henriques ADallanora, Benedet ALessa, Camargos EFrancisco, Rosa-Neto P, Nóbrega OToledo.  2018.  Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to.. Exp Gerontol.
Bernard-Gauthier V, Mossine AV, Mahringer A, Aliaga A, Bailey JJ, Shao X, Stauff J, Arteaga J, Sherman P, Grand'Maison M et al..  2018.  Identification of [F]TRACK, a Fluorine-18-Labeled Tropomyosin Receptor Kinase (Trk) Inhibitor for PET Imaging.. J Med Chem. 61(4):1737-1743.
Pascoal TA, Shin M, Kang MSu, Chamoun M, Chartrand D, Mathotaarachchi S, Bennacef I, Therriault J, Ng KPin, Hopewell R et al..  2018.  In vivo quantification of neurofibrillary tangles with [F]MK-6240.. Alzheimers Res Ther. 10(1):74.
Gauthier S, Herrmann N, Rosa-Neto P.  2018.  Optimal use of cholinergic drugs in Alzheimer's disease.. Brain.
Zukotynski K, Kuo PH, Mikulis D, Rosa-Neto P, Strafella AP, Subramaniam RM, Black SE.  2018.  PET/CT of Dementia.. AJR Am J Roentgenol. 211(2):246-259.
Villeneuve S, Vogel JW, Gonneaud J, Binette APichet, Rosa-Neto P, Gauthier S, Bateman RJ, Fagan AM, Morris JC, Benzinger TLS et al..  2018.  Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease.. JAMA Neurol.
Guadagno A, Kang MSu, Devenyi GA, Mathieu AP, Rosa-Neto P, Chakravarty MM, C-D Walker.  2018.  Reduced resting-state functional connectivity of the basolateral amygdala to the medial prefrontal cortex in preweaning rats exposed to chronic early-life stress.. Brain Struct Funct.
Schilling LPorcello, Pascoal TA, Zimmer ER, Mathotaarachchi S, Shin M, Rieder CRoberto de, Gauthier S, Palmini A, Rosa-Neto P.  2018.  Regional Amyloid-β Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer's Dementia.. Mol Neurobiol.
Tardif CL, Devenyi GA, Amaral RSC, Pelleieux S, Poirier J, Rosa-Neto P, Breitner JCS, Chakravarty MM.  2018.  Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer's disease.. Hum Brain Mapp. 39(2):971-984.
Gauthier S, Ng KPin, Pascoal TA, Zhang H, Rosa-Neto P.  2018.  Targeting Alzheimer's Disease at the Right Time and the Right Place: Validation of a Personalized Approach to Diagnosis and Treatment.. J Alzheimers Dis.
Benedet AL, Yu L, Labbe A, Mathotaarachchi S, Pascoal TA, Shin M, Kang M-S, Gauthier S, Rouleau GA, Poirier J et al..  2018.   variant mitigates Alzheimer disease pathophysiology in vivo and postmortem.. Neurol Genet. 4(1):e216.
2019
Miron J, Picard C, Lafaille-Magnan M-E, Savard M, Labonte A, Breitner JCS, Rosa-Neto P, Auld D, Poirier J.  2019.  Association of TLR4 with Alzheimer's disease risk and presymptomatic biomarkers of inflammation.. Alzheimers Dement. 15(7):951-960.
Carter SF, Herholz K, Rosa-Neto P, Pellerin L, Nordberg A, Zimmer ER.  2019.  Astrocyte Biomarkers in Alzheimer's Disease.. Trends Mol Med.
Liebsch F, Kulic L, Teunissen C, Shobo A, Ulku I, Engelschalt V, Hancock MA, van der Flier WM, Kunach P, Rosa-Neto P et al..  2019.  Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression.. Nat Commun. 10(1):2240.
Jiang L, Oualkacha K, Didelez V, Ciampi A, Rosa-Neto P, Benedet AL, Mathotaarachchi S, Richards JBrent, Greenwood CMT.  2019.  Constrained instruments and their application to Mendelian randomization with pleiotropy.. Genet Epidemiol.
Bailey JJ, Kaiser L, Lindner S, Wüst M, Thiel A, Soucy J-P, Rosa-Neto P, Scott PJH, Unterrainer M, Kaplan DR et al..  2019.  First-in-Human Brain Imaging of [F]TRACK, a PET tracer for Tropomyosin Receptor Kinases.. ACS Chem Neurosci. 10(6):2697-2702.
Meyer P-F, Tremblay-Mercier J, Leoutsakos J, Madjar C, Lafaille-Maignan M-É, Savard M, Rosa-Neto P, Poirier J, Etienne P, Breitner JCS.  2019.  INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease.. Neurology. 92(18):e2070-e2080.
Lleó A, Alcolea D, Martínez-Lage P, Scheltens P, Parnetti L, Poirier J, Simonsen AH, Verbeek MM, Rosa-Neto P, Slot RER et al..  2019.  Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study.. Alzheimers Dement. 15(6):742-753.
Meyer P-F, Labonte A, Rosa-Neto P, Poirier J, Breitner JCS.  2019.  No apparent effect of naproxen on CSF markers of innate immune activation.. Ann Clin Transl Neurol. 6(6):1127-1133.
Hadoux X, Hui F, Lim JKH, Masters CL, Pébay A, Chevalier S, Ha J, Loi S, Fowler CJ, Rowe C et al..  2019.  Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease.. Nat Commun. 10(1):4227.
Schirrmacher R, Bailey JJ, Mossine AV, Scott PJH, Kaiser L, Bartenstein P, Lindner S, Kaplan DR, Kostikov A, Fricker G et al..  2019.  Radioligands for Tropomyosin Receptor Kinase (Trk) Positron Emission Tomography Imaging.. Pharmaceuticals (Basel). 12(1)
Ng KPin, Therriault J, Kang MSu, Struyfs H, Pascoal TA, Mathotaarachchi S, Shin M, Benedet AL, Massarweh G, Soucy J-P et al..  2019.  Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [F]THK5351 uptake in progressive supranuclear palsy.. Neuroimage Clin. 24:102091.
Therriault J, Wang S, Mathotaarachchi S, Pascoal TA, Parent M, Beaudry T, Shin M, Al B, Kang MS, Ng KP et al..  2019.  Rostral-Caudal Hippocampal Functional Convergence Is Reduced Across the Alzheimer's Disease Spectrum.. Mol Neurobiol.

Pages